ProCE Banner Activity


Partnering With Patients for Optimal Outcomes in Clostridioides difficile infections


Watch patients share their experiences and hear expert faculty discuss clinical practice guideline updates and their approach to individualizing patient regimens according to patient risk factors, including considerations for use of comedications.  

Pharmacists: 1.50 contact hours (0.15 CEUs)

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Nurses: 1.50 Nursing contact hours

Released: March 21, 2023

Expiration: March 20, 2024

No longer available for credit.



Carolyn D. Alsonso

Carolyn D. Alsonso, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Harvard Medical School
Transplant & Immunocompromised Host ID Program
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Paul Feuerstadt

Paul Feuerstadt, MD, FACG, AGAF

Assistant Clinical Professor of Medicine
Attending Gastroenterologist
Department of Gastroenterology
Yale University School of Medicine
PACT-Gastroenterology Center
Hamden, Connecticut

Kevin Garey

Kevin Garey, PharmD, MS

Professor and Chair
Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by an educational grant from

Merck Sharp & Dohme Corp.


Peggy Lillis Foundation

ProCE Banner

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with Clostridioides difficile infections.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge, competence, and performance in applying the latest practice guidelines and data to provide patient-centered care in the management of Clostridioides difficile infections.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Accurately compare new clinical practice guidelines on CDI management to apply best practices to individual clinical scenarios

  • In partnership with patients, develop tailored and comprehensive treatment plans for CDI 

  • Integrate co-medications into CDI regimens to optimize long-term outcomes


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Carolyn D. Alonso, MD: consultant/advisor/speaker: AiCuris, Cidara, Merck; researcher: Merck.

Paul Feuerstadt, MD, FACG, AGAF: consultant/advisor/speaker: Ferring/Rebiotix, Merck, SERES Therapeutics, Summit Therapeutics.

Kevin Garey, PharmD, MS: researcher: Acurx Pharmaceuticals, Paratek Pharmaceuticals, Seres Therapeutics, Summit Pharmaceuticals.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 21, 2023, through March 20, 2024:

  1. Create an account or Login at
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Credit Designation 
CCO designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.50 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.50 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number -  JA4008176-0000-23-082-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.